Estimated CIR according to classifier, WBC count, and MRD
| WBC count (×109/L) . | Classifier . | MRD ≥10−4 . | Prevalence, n (%) . | 5-y CIR (%) . | Clinical risk classification . |
|---|---|---|---|---|---|
| <200 | gLoR | No | 58/191 (30.3) | 1.7 | Low |
| ≥200 | gLoR | No | 13/191 (6.8) | 17.5 | Intermediate |
| <200 | gHiR | No | 30/191 (15.7) | 24.8 | Intermediate |
| ≥200 | gHiR | No | 13/191 (6.8) | 38.4 | High |
| <200 | gLoR | Yes | 21/191 (11.0) | 28.9 | Intermediate |
| ≥200 | gLoR | Yes | 7/191 (3.7) | 28.6 | Intermediate |
| <200 | gHiR | Yes | 33/191 (17.3) | 41.5 | High |
| ≥200 | gHiR | Yes | 16/191 (8.4) | 45.8 | High |
| WBC count (×109/L) . | Classifier . | MRD ≥10−4 . | Prevalence, n (%) . | 5-y CIR (%) . | Clinical risk classification . |
|---|---|---|---|---|---|
| <200 | gLoR | No | 58/191 (30.3) | 1.7 | Low |
| ≥200 | gLoR | No | 13/191 (6.8) | 17.5 | Intermediate |
| <200 | gHiR | No | 30/191 (15.7) | 24.8 | Intermediate |
| ≥200 | gHiR | No | 13/191 (6.8) | 38.4 | High |
| <200 | gLoR | Yes | 21/191 (11.0) | 28.9 | Intermediate |
| ≥200 | gLoR | Yes | 7/191 (3.7) | 28.6 | Intermediate |
| <200 | gHiR | Yes | 33/191 (17.3) | 41.5 | High |
| ≥200 | gHiR | Yes | 16/191 (8.4) | 45.8 | High |
Patients were classified into 3 clinical risk groups according to 5-year CIR.